Mirum Pharmaceuticals: Stock Moves and Business Snapshot

Mirum Pharmaceuticals (MIRM) has seen its share price move recently, and investors are revisiting the biopharma name with its focus on rare and orphan liver diseases and a growing commercial portfolio.

The recent 2.2% 1 day share price return, 15.4% 30 day share price return and very large 5 year total shareholder return suggest momentum has been building for Mirum, as investors react to its expanding rare disease franchise and changing risk perceptions.

If Mirum has caught your attention and you are curious about other health related opportunities, take a look at our screener of 25 healthcare AI stocks as a starting point for fresh ideas.

With Mirum’s shares up strongly over the past year yet still trading below some valuation estimates, the key question for you is whether there is still mispricing here or if the market is already factoring in future growth.

Most Popular Narrative: 1.4% Undervalued

Mirum Pharmaceuticals’ most followed fair value estimate of $106.60 sits slightly above the last close at $105.10, so the current price is already close to that narrative view.

The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

Curious what kind of revenue ramp and margin profile justify that fair value, plus the earnings multiple baked into it? The full narrative lays out the numbers behind that $106.60 figure and the discount rate used to bring those cash flows back to today.

Result: Fair Value of $106.60 (UNDERVALUED)

However, there is still meaningful execution risk, with heavy reliance on Livmarli and important late stage PSC data that could shift sentiment quickly if the outcomes disappoint.

Next Steps

Given the mix of optimism and concern running through this story, it is worth checking the numbers for yourself and forming your own view quickly. You can anchor that view by looking at our breakdown of 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Mirum sits on your watchlist now, do not stop there, use the Simply Wall Street Screener to uncover more targeted ideas that fit your style.

• Target steady compounding potential by scanning our list of 13 dividend fortresses that aim to combine income with resilience.
• Hunt for value by checking out screener containing 24 high quality undiscovered gems, where under-the-radar names with solid fundamentals might still be off most investors’ radar.
• Prioritise capital preservation by reviewing 80 resilient stocks with low risk scores, built for investors who want sturdier balance sheets and milder swings in returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.